Del 17 i serien Resistance to Targeted Anti-Cancer Therapeutics

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

Inbunden, Engelska, 2018

1 719 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.

Produktinformation

Utgivningsdatum2018-04-13
Mått155 x 235 x 14 mm
Vikt401 g
FormatInbunden
SpråkEngelska
SerieResistance to Targeted Anti-Cancer Therapeutics
Antal sidor138
FörlagSpringer International Publishing AG
ISBN9783319751832

Tillhör följande kategorier

Onkologi inom Medicin
Medicinsk utrustning och medicinska tekniker inom Medicin

Andrés J. M. Ferreri has a degree in Medicine from the Facultad de Medicina of the Universidad de Buenos Aires, Argentina (1985), and obtained the degree of Doctor in Medicine and Surgery in the Facoltà di Medicina e Chirurgia dell’Università degli Studi di Parma, Italy, in 1992. He is a Specialist in Clinical Oncology (Università degli Studi di Milan, Italy, 2005). He was a research fellow at the Divisione di Oncologia Sperimentale “E” and at the Divisione di Oncologia Médica “A” of the Istituto Nazionale dei Tumori of Milan (1989–1994) and vice-director of the Medical Oncology Unit of the San Raffaele Scientific Institute of Milan, Italy. Currently, Dr. Ferreri is Head of the Unit of Lymphoid Malignancies of the San Raffaele Scientific Institute of Milan, and is a Contract Professor of Oncology in the Vita e Salute University, Milan. He is fully devoted to the research on non-Hodgkin lymphomas and is an opinion leader in the field of extranodal lymphomas. Dr. Ferreri is Associate Editor of the ESO/START Project and of “Haematological Oncology” and Faculty of the European School of Oncology. Dr. Ferreri is a member of EHA, ESMO, ASH, and ASCO.

Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents.- Chapter 2 BCL2 Inhibitors: insights into resistance.- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib.- Chapter 4 IMiD – immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms.- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents.- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.